Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - Yake Biotechnology
Alternative Names: Anti-CD19 CART cell therapy - Yake BiotechnologyLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Yake Biotechnology
- Developer Yake Biotechnology; Zhejiang University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma
- No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in China (IV, Infusion)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(Second-line therapy or greater) in China (IV, Infusion)
- 15 Feb 2022 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater, Combination therapy) in China (Parenteral) (NCT05239676)